Hims & Hers Health shares rose 8% to $29.58 on Wednesday as CEO Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit over data sharing, advertising, subscription and prescribing practices. In a CNBC interview, Dudum said the dispute reflected regulators’ difficulty understanding a business that is rebuilding healthcare through a digital model, and suggested the FTC wanted "more of a headline" than an agreement. The lawsuit accuses Hims & Hers of sharing sensitive user health information with advertisers including Meta and Snap, charging for prescriptions before customers spoke with a healthcare provider, and making subscriptions difficult to cancel. Dudum said the company’s model is intended to expand access to care. He also discussed Hims & Hers’ shift from compounded GLP-1 drugs to branded treatments. The company sold discounted copycat versions during industry-wide shortages, before Novo Nordisk filed a patent infringement lawsuit after supply recovered. Novo dropped the case in March after Hims & Hers agreed to offer its branded medicines on the platform. Dudum expects monthly out-of-pocket prices for cash-paying patients to fall to $40 to $50 from roughly $150 to $200, depending on the medication format. Dudum said Hims & Hers is increasing investment to become an AI-native company and is moving away from third-party AI agents in favor of capabilities built entirely in house.